IDEXX vs. DHR vs. TMO: Earnings Preview Ahead of Q4 Reports
Key Takeaways
-
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics.
-
Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
-
IDEXX’s focused veterinary diagnostics model delivers higher margins than DHR and TMO’s diversified portfolios, though all three face pressures from U.S. visit trends and constrained research funding.
-
Each company exceeded expectations in Q3: IDEXX posted $1.105 billion in revenue (+13% YoY), DHR $6.1 billion (+4.5% YoY), and TMO $11.12 billion (+5% YoY).
-
Consensus Q4 EPS estimates are approximately $2.93 for IDEXX, $2.15 for Danaher, and $6.45 for Thermo Fisher, with 2026 guidance a key catalyst.
-
Investor sentiment currently favors IDEXX’s pet-health exposure over peers’ heavier reliance on biotech spending.
Earnings Context and Why This Comparison Matters
IDEXX Laboratories’ upcoming Q4 report underscores its leadership in veterinary diagnostics, a resilient $50+ billion market growing an estimated 7–10% annually as pet ownership and spending rise globally. Comparing IDEXX with Danaher and Thermo Fisher—two diversified leaders in human diagnostics and life sciences—highlights a key trade-off: IDEXX’s high-margin, recurring revenue base versus the scale and breadth, but greater cyclicality, of its peers.
All three delivered solid Q3 results, reinforcing sector durability. However, IDEXX’s accelerating international growth and steady innovation pipeline, including new analyzer platforms, position it as a potential standout as investors seek defensive growth amid delayed funding cycles and policy uncertainty.
IDEXX Laboratories (IDXX): Earnings Focus
Analysts expect Q4 revenue of roughly $1.07 billion and EPS near $2.93, supported by 7–10% organic growth in Companion Animal Group diagnostics. Growth drivers include recurring consumables revenue, premium instrument placements, and net pricing gains.
Key indicators to watch include trends in U.S. clinical visits, where recent declines have begun to ease, international performance, which continues to deliver double-digit growth, and adoption of newer offerings such as Cancer Dx and the inVue Dx analyzer. Historically, IDEXX has exceeded expectations by 6–9% on average, with shares often responding positively to upside surprises. Management’s 2026 outlook is likely to emphasize mid-to-high single-digit organic growth supported by continued innovation.
Danaher (DHR): Earnings Focus
Danaher reports Q4 results on January 28, with consensus estimates calling for approximately $6.8 billion in revenue and EPS of $2.15. This follows Q3 results of $6.1 billion in revenue and $1.89 in adjusted EPS, reflecting about 3% core growth.
Bioprocessing consumables remain Danaher’s strongest segment, while Diagnostics has been pressured by pricing reforms in China. Management has reaffirmed full-year EPS guidance of $7.70–$7.80 and continues to target productivity gains of roughly $250 million, supporting margins near 28%. While shares have lagged year to date due to life-sciences softness, Danaher’s operating discipline remains a long-term positive.
Thermo Fisher Scientific (TMO): Earnings Focus
Thermo Fisher is expected to report Q4 earnings in early February, with analysts projecting $11.9–12.0 billion in revenue and EPS around $6.45. In Q3, the company posted $11.12 billion in revenue with 3% organic growth and adjusted EPS of $5.79, alongside a 100-basis-point margin expansion to 23.3%.
Strength in pharma and biotech customers has helped offset weaker academic and government spending. Thermo recently raised full-year revenue guidance to $44.1–44.5 billion and EPS to $22.60–$22.86, underscoring its scale-driven resilience. Still, slower biopharma funding growth may cap upside relative to IDEXX’s veterinary tailwinds.
Head-to-Head Comparison
-
Growth: IDEXX leads with double-digit organic growth, while Danaher and Thermo deliver low-single-digit gains.
-
Valuation: IDEXX trades at a premium multiple reflecting its higher growth and margins; DHR and TMO offer more modest valuations tied to diversified exposure.
-
Margins and Stability: IDEXX’s “razor-and-blade” model supports superior margins, while DHR and TMO benefit from scale and diversified cash flows.
-
Risk Profile: IDEXX is less exposed to biotech funding volatility, though U.S. visit trends remain a risk. DHR and TMO face greater sensitivity to policy changes and research spending cycles.
AI-Based Market View
Tickeron AI Perspective
According to Tickeron’s AI models, IDEXX currently holds the highest probability of outperformance over the next 6–12 months, driven by strong earnings momentum, innovation-led growth, and attractive margins within a stable veterinary diagnostics market. Confirmation will hinge on Q4 results and management’s 2026 guidance, particularly around visit trends and international expansion.
Disclaimers and Limitations
IDXX in downward trend: price dove below 50-day moving average on January 20, 2026
IDXX moved below its 50-day moving average on January 20, 2026 date and that indicates a change from an upward trend to a downward trend. In of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on January 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IDXX turned negative on January 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for IDXX crossed bearishly below the 50-day moving average on January 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IDXX entered a downward trend on February 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IDXX's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
IDXX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.348) is normal, around the industry mean (12.030). P/E Ratio (48.115) is within average values for comparable stocks, (118.611). IDXX's Projected Growth (PEG Ratio) (3.740) is very high in comparison to the industry average of (1.533). IDXX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (11.848) is also within normal values, averaging (12.971).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties
Advertisement